Literature DB >> 20634641

A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I.

C A Carvajal1, C B Stehr, P A González, E M Riquelme, T Montero, M J Santos, A M Kalergis, C E Fardella.   

Abstract

UNLABELLED: Familial hyperaldosteronism type I (FH-I) is an autosomal dominant disorder caused by an unequal cross-over of the gene encoding steroid 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2), giving rise to a chimeric CYP11B1/CYP11B2 gene that displays aldosterone synthase activity regulated by ACTH instead of angiotensin II. AIM: To report an unprecedented case of a de novo unequal crossover mutation between CYP11B1 and CYP11B2 genes causing FH-I. PATIENTS AND METHODS: The index case is a 45-yr-old Chilean male diagnosed with primary aldosteronism (PA). All family members were also studied: his biological parents, 1 brother, 6 sisters, 2 daughters, and 1 son. Plasma renin activity, serum aldosterone, and its ratio were measured in all patients. Genetic analyses were performed using long-extension PCR (XL-PCR), DNA sequencing and Southern blot methods.
RESULTS: PA was diagnosed for the index case, 1 of his daughters, his son but not for his parents or siblings. XLPCR and Southern blotting demonstrated the presence of the chimeric CYP11B1/CYP11B2 gene solely in PA-affected subjects, suggesting a case of a de novo mutation. Sequence analysis showed the unequal cross-over CYP11B1/CYP11B2 at intron 2 (c.2600-273 CYP11B2). We also identified a polymorphism at the same intron (c.2600-145C>A CYP11B2) in the genome of the index case's father.
CONCLUSION: We describe an unprecedented case of unequal cross-over mutation for the chimeric CYP11B1/CYP11B2 gene causing FH-I, which may be linked to a polymorphism in the index case's father germ line.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634641     DOI: 10.1007/BF03347044

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

1.  Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: the AmpFlSTR Identifiler PCR Amplification Kit.

Authors:  Patrick J Collins; Lori K Hennessy; Craig S Leibelt; Rhonda K Roby; Dennis J Reeder; Paul A Foxall
Journal:  J Forensic Sci       Date:  2004-11       Impact factor: 1.832

2.  Molecular epidemiology of factor IX germline mutations in Mexican Hispanics: pattern of mutation and potential founder effects.

Authors:  E C Thorland; B G Weinshenker; J Z Liu; R P Ketterling; E L Vielhaber; C K Kasper; R Ambriz; R Paredes; S S Sommer
Journal:  Thromb Haemost       Date:  1995-12       Impact factor: 5.249

3.  Germline mosaicism in a female who seemed to be a carrier by sequence analysis.

Authors:  S S Sommer; A Knöll; C R Greenberg; R P Ketterling
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

4.  Aldosterone biosynthesis in the rat brain.

Authors:  C E Gomez-Sanchez; M Y Zhou; E N Cozza; H Morita; M F Foecking; E P Gomez-Sanchez
Journal:  Endocrinology       Date:  1997-08       Impact factor: 4.736

5.  Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism.

Authors:  T Ogishima; H Shibata; H Shimada; F Mitani; H Suzuki; T Saruta; Y Ishimura
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

6.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

7.  The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex.

Authors:  K M Curnow; M T Tusie-Luna; L Pascoe; R Natarajan; J L Gu; J L Nadler; P C White
Journal:  Mol Endocrinol       Date:  1991-10

8.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

9.  Aldosterone biosynthesis and action in vascular cells.

Authors:  R Takeda; H Hatakeyama; Y Takeda; K Iki; I Miyamori; W P Sheng; H Yamamoto; I A Blair
Journal:  Steroids       Date:  1995-01       Impact factor: 2.668

10.  Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene.

Authors:  P Mulatero; F Veglio; C Pilon; F Rabbia; C Zocchi; P Limone; M Boscaro; N Sonino; F Fallo
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  3 in total

1.  Pregnancy normalized familial hyperaldosteronism type I: a novel role for progesterone?

Authors:  C Campino; P Trejo; C A Carvajal; A Vecchiola; C Valdivia; C A Fuentes; J F Delgado; C F Lagos; M Aglony; C Carrasco; A Martinez-Aguayo; H García; C Loureiro; C E Fardella
Journal:  J Hum Hypertens       Date:  2014-06-19       Impact factor: 3.012

2.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

3.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.